Skip to content
Open access

748. Tau Pathology Modulates the Association Between Neurodegeneration and Depressive Symptoms in Alzheimer’s Disease

Sep 2026 · International Journal of Neuropsychopharmacology · Vol 29, pp. i64 - i65 · 0 citations

TL;DR

The findings indicate that the relationship between neurodegeneration and depression is stage-dependent and substantially modulated by tau pathology, and the importance of considering both proteopathic stage and preserved insight when interpreting affective symptoms across the Alzheimer’s disease continuum.

Abstract

Abstract Background The moderating role of tau pathology in the association between neurodegeneration and depression across the Alzheimer’s disease continuum remains insufficiently characterized. Aims & Objectives This study aimed to examine whether tau pathology modifies the relationship between neurodegeneration markers and depressive symptoms in older adults spanning the Alzheimer’s disease continuum. Method A total of 103 older adults were included. Depressive symptoms were assessed using the Cornell Scale for Depression in Dementia (CSDD), Hamilton Depression Rating Scale (HAM-D), and Geriatric Depression Scale Short Version (GDS-SV). Neurodegeneration markers included lateral ventricular volume (LVV), hippocampal volume, gray matter volume, and white matter hyperintensity volume. Tau pathology was evaluated using Braak stage classification and tau PET standardized uptake value ratios (SUVR). Generalized linear models were applied to test interaction effects between neurodegeneration markers and tau pathology, with multiple comparisons controlled using Benjamini-Hochberg false discovery rate correction. Sensitivity analyses employed continuous tau SUVR values. Results A robust interaction between LVV and advanced tau pathology (Braak stage V/VI) was observed, most prominently for self-reported depressive symptoms measured by the GDS-SV. LVV was positively associated with depressive symptoms at lower tau stages, whereas this association attenuated or reversed at more advanced tau stages. Although interactions involving other neurodegeneration markers did not survive strict false discovery rate correction, they demonstrated consistent stage-dependent patterns. Sensitivity analyses using continuous tau SUVR confirmed that significant associations were confined to lower SUVR ranges. Discussion & Conclusions These findings indicate that the relationship between neurodegeneration and depression is stage-dependent and substantially modulated by tau pathology. The prominence of this interaction in self-reported depressive symptoms underscores the importance of considering both proteopathic stage and preserved insight when interpreting affective symptoms across the Alzheimer’s disease continuum.

Read PDF

Similar papers

Open access Aug 2026

Tracking the Continuous Time Dynamics of Tau and Depressive Symptoms across the Alzheimer's Disease Continuum

In aging and Alzheimer's disease (AD), higher levels of tau pathology often coincide with an increased number of depressive symptoms. To establish probable causality between tau accumulation and depressive symptom trajectories, we applied three complementary analysis approaches using longitudinal positron emission tomo...

Teodora Z. Markova, Margo B. Heston, Anne S. Berry · 0 citations
Open access Jul 2026

Linking cognitive variability and Alzheimer's disease biomarkers by neurocognitive status

Abstract INTRODUCTION This study aimed to assess intra‐individual cognitive variability (IICV) in relation to Alzheimer's disease (AD) biomarkers. METHODS The National Alzheimer's Coordinating Center sample (n = 879), aged 50+ with a complete neuropsychological evaluation and AD biomarker data available (64% cognitivel...

S. S. Lin, Alicia L. Milam, Andrew Kiselica et al. · 0 citations
Sep 2026

Alzheimer's Co-Pathology Burden on Basal Forebrain Atrophy and Cognitive Impairment in Dementia with Lewy Bodies: A Cross-Sectional Pilot Study.

OBJECTIVE Dementia with Lewy Bodies (DLB) is the second most common neurodegenerative dementia after Alzheimer's disease (AD), with significant pathological overlap between the two conditions. However, the impact of Alzheimer's co-pathology on basal forebrain (BF) atrophy and its relationship with neurodegeneration and...

Daniele Urso, Thomas Giannelli, B. Tafuri et al. · 0 citations
Review Open access Sep 2026

Alzheimer’s Disease in the Era of Geroscience: Mechanisms, Biomarkers, and Therapeutic Prospects

Alzheimer’s disease (AD) is the leading cause of dementia and a heterogeneous neurodegenerative disorder characterized by amyloid-β (Aβ) and tau pathology, impaired proteostasis, neurovascular dysfunction, maladaptive glial and immune responses, and synaptic dysfunction. Human genetic evidence supports an upstream role...

P. Chmielewski · 0 citations
Sep 2026

Joint impact of pathological burden and cognitive resilience on Alzheimer's disease risk.

The findings broaden the understanding that AD dementia is shaped jointly by pathological burden and cognitive resilience, and argue for therapeutic trial and prevention strategies that strengthen resilience alongside reducing pathology.

Zhi-Bo Wang, Shu-Heng Wang, Yu-Mei Liang et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.